{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:45:27Z","timestamp":1785725127651,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017480","name":"Chang Bing Show Chwan Memorial Hospital","doi-asserted-by":"publisher","award":["SRD-109014"],"award-info":[{"award-number":["SRD-109014"]}],"id":[{"id":"10.13039\/501100017480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC112-2314-B-008-005-MY3"],"award-info":[{"award-number":["NSTC112-2314-B-008-005-MY3"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC114-2811-B-008-002"],"award-info":[{"award-number":["NSTC114-2811-B-008-002"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC112-2314-B-442-002-MY3"],"award-info":[{"award-number":["NSTC112-2314-B-442-002-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2811-B-039-028"],"award-info":[{"award-number":["NSTC113-2811-B-039-028"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218694","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:43:27Z","timestamp":1783147407000},"page":"218694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An IL-15 fusion with albumin-binding domain boosts immunotherapy therapy in glioblastoma via FGF-2 competition regulating FGFR1\/2"],"prefix":"10.1016","volume":"657","author":[{"given":"Yueh-Shan","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Tsang","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-Cheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Li","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Liang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2153-340X","authenticated-orcid":false,"given":"Fei-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218694_bib1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s13311-022-01251-6","article-title":"Updates in IDH-wildtype glioblastoma","volume":"19","author":"Melhem","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.canlet.2026.218694_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for glioblastoma: the promise of combination strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218694_bib3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.ijrobp.2009.05.031","article-title":"Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide","volume":"77","author":"Weiler","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2026.218694_bib4","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3389\/fimmu.2020.01508","article-title":"Clinical and recent patents applications of PD-1\/PD-L1 targeting immunotherapy in cancer treatment-current progress, strategy, and future perspective","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218694_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110621","article-title":"Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1","volume":"130","author":"Fan","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218694_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112949","article-title":"Hyperprogression, a challenge of PD-1\/PD-L1 inhibitors treatments: potential mechanisms and coping strategies","volume":"150","author":"Zhao","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218694_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218694_bib8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218694_bib9","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218694_bib10","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2020.38.15_suppl.2511","article-title":"Barbara Jane O'Brien, and John Frederick De Groot, Phase I\/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM)","volume":"38","author":"Shiao-Pei","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218694_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107318","article-title":"Biological effects of IL-15 on immune cells and its potential for the treatment of cancer","volume":"91","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218694_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108677","article-title":"Development of a recombinant human IL-15.sIL-15Ralpha\/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model","volume":"112","author":"Zhao","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218694_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081789","article-title":"Preclinical evaluation of recombinant human IL15 protein fused with albumin binding domain on Anti-PD-L1 immunotherapy efficiency and anti-tumor immunity in Colon cancer and melanoma","volume":"13","author":"Hsu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218694_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-022-01363-2","article-title":"Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness","volume":"10","author":"Gabler","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.canlet.2026.218694_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cells8070715","article-title":"Fibroblast growth factor receptor functions in glioblastoma","volume":"8","author":"Jimenez-Pascual","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218694_bib16","first-page":"475","article-title":"FGFR-TACC gene fusions in human glioma","volume":"19","author":"Lasorella","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218694_bib17","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.immuni.2015.06.024","article-title":"Growth factor FGF2 cooperates with Interleukin-17 to repair intestinal epithelial damage","volume":"43","author":"Song","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218694_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12943-024-02167-9","article-title":"Clinical advances and challenges in targeting FGF\/FGFR signaling in lung cancer","volume":"23","author":"Peng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218694_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","article-title":"Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease","volume":"94","author":"Durlacher-Betzer","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.canlet.2026.218694_bib20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218694_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.29686","article-title":"Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model","volume":"138","author":"Mathios","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218694_bib22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s13311-022-01194-y","article-title":"Regorafenib reverses temozolomide-induced CXCL12\/CXCR4 signaling and triggers apoptosis mechanism in glioblastoma","volume":"19","author":"Chiang","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.canlet.2026.218694_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0165-5728(95)00146-8","article-title":"Mouse microglial cell lines differing in constitutive and interferon-\u03b3-inducible antigen-presenting activities for naive and memory CD4+ and CD8+ T cells","volume":"63","author":"Walker","year":"1995","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.canlet.2026.218694_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jcp.1041250307","article-title":"Transformation of mouse bone marrow cells by transfection with a human oncogene related to c-myc is associated with the endogenous production of macrophage colony stimulating factor 1","volume":"125","author":"Sklar","year":"1985","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2026.218694_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fncel.2013.00045","article-title":"Origin and differentiation of microglia","volume":"7","author":"Ginhoux","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.canlet.2026.218694_bib26","doi-asserted-by":"crossref","DOI":"10.23876\/j.krcp.25.047","article-title":"CRISPR\/Cas9-based SLC12A3 gene knock in: a model for cellular feature analysis in Gitelman syndrome","author":"Lim","year":"2026","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.canlet.2026.218694_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2026.218694_bib28","first-page":"3577","article-title":"Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15","volume":"60","author":"Kobayashi","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218694_bib29","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.7150\/ijbs.82266","article-title":"A novel isotope-labeled small molecule probe CC12 for anti-glioma via suppressing LYN-Mediated progression and activating apoptosis pathways","volume":"19","author":"Huang","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2026.218694_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-022-01363-2","article-title":"Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness","volume":"10","author":"Gabler","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.canlet.2026.218694_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112661","article-title":"Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma","volume":"147","author":"Chiang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218694_bib32","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1096\/fasebj.13.13.1677","article-title":"FGF-2\/fibroblast growth factor receptor\/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling","volume":"13","author":"Padera","year":"1999","journal-title":"Faseb j"},{"key":"10.1016\/j.canlet.2026.218694_bib33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ijpharm.2016.07.046","article-title":"Fusion of an albumin-binding domain extends the half-life of immunotoxins","volume":"511","author":"Guo","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.canlet.2026.218694_bib34","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","article-title":"Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy","volume":"10","author":"Lin","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218694_bib35","doi-asserted-by":"crossref","first-page":"E10915","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218694_bib36","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1016\/j.ymthe.2024.10.021","article-title":"A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses","volume":"32","author":"Shi","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218694_bib37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fcell.2019.00331","article-title":"Fibroblast growth factor 2 protein stability provides decreased dependence on heparin for induction of FGFR signaling and alters ERK signaling dynamics","volume":"7","author":"Koledova","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2026.218694_bib38","doi-asserted-by":"crossref","first-page":"16868","DOI":"10.1074\/jbc.M011226200","article-title":"Binding of heparin\/heparan sulfate to fibroblast growth factor receptor 4","volume":"276","author":"Loo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218694_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14728222.2020.1736558","article-title":"FGF2: a novel druggable target for glioblastoma?","volume":"24","author":"Jimenez-Pascual","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2026.218694_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.153924","article-title":"Hypocrellin A exerts antitumor effects by inhibiting the FGFR1 signaling pathway in non-small cell lung cancer","volume":"97","author":"Yang","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.canlet.2026.218694_bib41","article-title":"Activation of FGFR2 signaling suppresses BRCA1 and drives triple-negative mammary tumorigenesis that is sensitive to immunotherapy","volume":"8","author":"Lei","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218694_bib42","doi-asserted-by":"crossref","first-page":"14839","DOI":"10.1074\/jbc.RA118.002907","article-title":"Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-kappaB signaling in prostate cancer cells","volume":"293","author":"Wang","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218694_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40824-023-00360-3","article-title":"Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway","volume":"27","author":"Li","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.canlet.2026.218694_bib44","article-title":"Recent advancements and strategies for overcoming the blood-brain barrier using albumin-based drug delivery systems to treat brain cancer, with a focus on glioblastoma","volume":"15","author":"Tincu Iurciuc","year":"2023","journal-title":"Polymers"},{"key":"10.1016\/j.canlet.2026.218694_bib45","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.canlet.2026.218694_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113618","article-title":"Focus on immune checkpoint PD-1\/PD-L1 pathway: new advances of polyphenol phytochemicals in tumor immunotherapy","volume":"154","author":"Liu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218694_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218694_bib48","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218694_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13129","article-title":"Targeting regulatory T cells in anti-PD-1\/PD-L1 cancer immunotherapy","volume":"95","author":"Zhulai","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.canlet.2026.218694_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218694_bib51","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","article-title":"Breaking barriers for glioblastoma with a path to enhanced drug delivery","volume":"14","author":"Noorani","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218694_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1471-4159.2008.05390.x","article-title":"Permeation of blood-borne IL15 across the blood-brain barrier and the effect of LPS","volume":"106","author":"Pan","year":"2008","journal-title":"J. Neurochem."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:20:18Z","timestamp":1785723618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":52,"alternative-id":["S0304383526004581"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218694","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An IL-15 fusion with albumin-binding domain boosts immunotherapy therapy in glioblastoma via FGF-2 competition regulating FGFR1\/2","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218694"}}